The AfterRaise week
78 rounds, $6.9B of announced capital. The largest: Stegra raised €1.4B. Sorted by size; every figure links to its source.
The announcement did not set out what the funding supports.
The company said the funding supports scale its high-performance computational infrastructure, expand its advanced materials research divisions, and accelerate the commercialization of its molecular design platform.
The company said the funding supports accelerate its innovation roadmap, expand production capacity, strengthen its global customer support organization, and deepen collaborative R&D with semiconductor manufacturers.
The company said the funding supports support global Phase 3 trials of OLN324, a potential VEGF/Ang2 antibody addressing causes of vision loss in the $15 billion retina market Founded in 2023, Ollin Biosciences is a clinical-stage biopharmaceutical company dedicated to acquiring and developing therapies for vision-threatening diseases.
The company said the funding supports accelerate product development across autonomous finance and agentic commerce, expand its infrastructure and regulatory footprint into new markets, and continue scaling the teams building its new AI native financial software.
The company said the funding supports fund the acquisition, development, and expansion of its purpose-built autonomous vehicle (AV) and commercial electric vehicle (EV) charging depots across the United States.
The company said the funding supports support continued investment in product development, expansion of its engineering and implementation teams, international growth, and a liquidity opportunity for employees.
The company said the funding supports secure high-performance graphics processing unit (GPU) compute clusters, expand its specialized scientific data-ingestion repositories, and aggressively recruit elite machine learning researchers and computational scientists.
The company said the funding supports advance its current pipeline of multiple programs and scale its discovery and development process.
The company said the funding supports scale the business and accelerate delivery of its advanced AI-native networking technology.
The company said the funding supports expand operations and its R&D efforts.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports support clinical development of lead programme RQB01 designed to provide seasonal influenza protection with a single administration Led by CEO Mike Westby, RQ Bio is a biotechnology company developing long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-ris.
The company said the funding supports further enhance its AI solutions for complex banking and insurance use cases, and expand its global footprint across the US, EMEA, and LATAM.
The company said the funding supports expand its corporate go-to-market teams, scale its engineering presence, and accelerate the core development of its proprietary operating system, "Trase Origin." Led by Co-founder and CEO Grant Verstandig alongside President Baskar Sridharan, Trase develops an AI-native operating system engineered to build, run, and govern secure AI agents across cloud, on-premises, and edge infrastructures for hi.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports invest in the platform and developer experience, expand the team across engineering and developer relations.
The company said the funding supports accelerate its expansion across new health systems, advancement of its AI agents, and growth in value-based care models.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports support product development, artificial intelligence initiatives, and its international expansion.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports expand into additional asset classes, including equities, perpetuals, and prediction markets, while continuing to invest in its broader trading and social platform.
The company said the funding supports accelerate the development of the clinical pipeline, including the Phase 1b/2a study of NB-4746, its oral, brain-penetrant SARM1 inhibitor, which recently commenced dosing in ALS patients.
The company said the funding supports the initial clinical development of LBL-051, its tri-specific T-cell engager, designed to achieve a broad immune system reset to treat patients suffering from a range of refractory autoimmune diseases.
The company said the funding supports invest in deeper AI agents, expand its automated tax and compliance infrastructure, and scale its in-person workforce in New York from 50 to 200 employees over the next year.
The company said the funding supports expand its research organization, grow its software engineering teams, and acquire the computational infrastructure required to scale its digital simulation environments.
The company said the funding supports accelerate its official market expansion into the United States, scale its corporate footprint in the Austin region, and actively recruit talent across its engineering, business development, and product management divisions.
The company said the funding supports help grow its client base, expand its advisory team, and continue to develop its platform and brand.
The company said the funding supports support the continued expansion of the clinical clarity layer to turn fragmented medical records into decision-ready clinical data.
The company said the funding supports advance its portfolio of antibodies targeting clinically validated pathways for migraine prevention.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports scale its go-to-market operations to meet surging demand, expand its software engineering capabilities, and grow its customer success teams to manage national deployments.
The company said the funding supports expand operations and its development efforts.
The company said the funding supports expand its agentic compliance software across the broader industrial economy, accelerate global market expansion, and scale its specialized engineering and regulatory audit teams.
The announcement did not set out what the funding supports.
The company said the funding supports advance its lead intranasal prophylactic antiviral candidate toward Phase 2b readiness, expand its proprietary glycan-targeted platform, support ongoing manufacturing operations, and establish its primary corporate infrastructure in the United States.
The company said the funding supports build its team and expand its work with global enterprises.
The company said the funding supports expand operaitons and its development efforts.
The company said the funding supports expand its engineering and customer-facing teams, deepen integrations across the largest EHR platforms, and accelerate adoption across provider groups and health systems.
The Daily Brief
Every disclosed US, UK and European round of $5M or more, with what each company said the money supports, the morning it is observed. One email, only on days something happened, unsubscribe with one click.